Show simple item record

dc.contributor.authorTopaloğlu Demir, Filiz
dc.contributor.authorÖzkök Akbulut, Tuğba
dc.contributor.authorKıvanç Altunay, İlknur
dc.contributor.authorAytekin, Sema
dc.contributor.authorTopal, İlteriş Oğuz
dc.contributor.authorKara Polat, Asude
dc.contributor.authorÖzkur, Ezgi
dc.contributor.authorKaradağ, Ayşe Serap
dc.date.accessioned2021-01-27T08:14:57Z
dc.date.available2021-01-27T08:14:57Z
dc.date.issued2020en_US
dc.identifier.citationTopaloğlu Demir, F., Özkök Akbulut, T., Kıvanç Altunay, İ., Aytekin, S., Topal, İ. O., Kara Polat, A. ... Karadağ, A. S. (2020). Evaluation of the adverse effects of biological agents used in the treatment of psoriasis: A multicenter retrospective cohort study. Dermatologic Therapy, 33(6). https://dx.doi.org/10.1111/dth.14216en_US
dc.identifier.issn1396-0296
dc.identifier.issn1529-8019
dc.identifier.urihttps://dx.doi.org/10.1111/dth.14216
dc.identifier.urihttps://hdl.handle.net/20.500.12511/6410
dc.description.abstractThe objective was to reveal and compare the adverse effects of infliximab, etanercept, adalimumab, ustekinumab and secukinumab, and determine possible risk factors. The follow-up files and computer-based records of patients with psoriasis were retrospectively screened between January 2007 and September 2019. The five biological agents were compared in terms of their adverse effects, and factors that might be related to these effects were explored. While there was no statistically significant difference between the agents in terms of the rate of serious adverse effects, when all the adverse effects were evaluated together, the highest rate was seen in the use of infliximab and the lowest in secukinumab (P= .001). The rates of adverse effects and related drug discontinuation were higher in the use of anti-TNF agents compared to interleukin inhibitors (P= .004 andP= .012, respectively). The agent with the highest drug discontinuation rate due to adverse effects was infliximab while the least discontinued agent was ustekinumab (P= .036). There were more side effects with anti-TNF than interleukin inhibitors, but the serious adverse effect rate was similar in both groups. The incidence of certain adverse effects increases depending on age, number of comorbidities, biological agent and its group, concomitant systemic therapy, and use of multiple agents.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectAdverse Effectsen_US
dc.subjectBiological Agentsen_US
dc.subjectPsoriasisen_US
dc.subjectSafetyen_US
dc.titleEvaluation of the adverse effects of biological agents used in the treatment of psoriasis: A multicenter retrospective cohort studyen_US
dc.typearticleen_US
dc.relation.journalDermatologic Therapyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Deri ve Zührevi Hastalıklar Ana Bilim Dalıen_US
dc.authorid0000-0002-2049-1316en_US
dc.identifier.volume33en_US
dc.identifier.issue6en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1111/dth.14216en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record